MoonLake Immunotherapeutics Faces Class Action for Securities Fraud Allegations
Written by Emily J. Thompson, Senior Investment Analyst
Source: PRnewswire
Updated: 1 hour ago0mins
- Lawsuit Background: MoonLake Immunotherapeutics (MLTX) is facing a class action lawsuit for failing to disclose that its product SLK shares molecular targets with BIMZELX, resulting in investor losses from March 10, 2024, to September 29, 2025, which could negatively impact the company's reputation and stock price.
- Fraud Allegations: The lawsuit alleges that MoonLake's positive statements lacked a reasonable basis, misleading investors about the company's business and prospects, potentially leading to future legal and financial risks.
- Investor Action: Affected investors must participate in the lawsuit by December 15, 2025, to become lead plaintiffs, highlighting investor concerns regarding the company's transparency and compliance.
- Legal Consultation: Investors can contact the Law Offices of Frank R. Cruz for more information, indicating the potential impact of legal issues on the company and the erosion of investor confidence.
MLTX.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on MLTX
Wall Street analysts forecast MLTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLTX is 15.38 USD with a low forecast of 5.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
10 Buy
5 Hold
2 Sell
Moderate Buy
Current: 14.900
Low
5.00
Averages
15.38
High
30.00
Current: 14.900
Low
5.00
Averages
15.38
High
30.00
Cantor Fitzgerald
Prakhar Agrawal
Overweight
maintain
2025-12-04
New
Reason
Cantor Fitzgerald
Prakhar Agrawal
Price Target
2025-12-04
New
maintain
Overweight
Reason
STAT reports that the FDA plans to shift toward requiring only one pivotal trial for approval rather than the traditional two, though details and timing remain unclear pending formal agency communication, Cantor Fitzgerald analyst Prakhar Agrawal tells investors in a research note. While the policy could have broad sector implications, it meaningfully boosts the likelihood of MoonLake's sonelokimab securing hidradenitis suppurativa approval based on a single positive pivotal study, the analyst says. Cantor has an Overweight rating on MoonLake shares.
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$30 -> $26
2025-11-21
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$30 -> $26
2025-11-21
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on MoonLake Immunotherapeutics to $26 from $30 and keeps a Buy rating on the shares. The firm cites the Q3 results and completed equity financing for the target drop.
Goldman Sachs
Neutral
maintain
$7 -> $8
2025-11-06
Reason
Goldman Sachs
Price Target
$7 -> $8
2025-11-06
maintain
Neutral
Reason
Goldman Sachs raised the firm's price target on MoonLake Immunotherapeutics to $8 from $7 and keeps a Neutral rating on the shares.
Oppenheimer
Oppenheimer
Outperform
maintain
$25 -> $30
2025-11-06
Reason
Oppenheimer
Oppenheimer
Price Target
$25 -> $30
2025-11-06
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on MoonLake Immunotherapeutics to $30 from $25 and keeps an Outperform rating on the shares. The firm notes MoonLake reported Q3 financials and provided a business update, including results from the Phase 2 LEDA study in palmo-plantar pustulosis, interim adolescent hidradenitis suppurativa data and interim long-term efficacy data from VELA-1/VELA-2.
See All Ratings
About MLTX
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What are the main allegations against MoonLake in the class action lawsuit?
Why did MoonLake's stock price drop nearly 90% after trial results?
How might the lawsuit impact MoonLake's future stock performance?
Will MoonLake's drug sonelokimab face regulatory challenges after the trial failure?